We need to mandate drug cost transparency on electronic medical records
- PMID: 29255097
- PMCID: PMC5738246
- DOI: 10.1503/cmaj.171070
We need to mandate drug cost transparency on electronic medical records
Conflict of interest statement
Competing interests: Iris Gorfinkel has received research grants from Astellas, Mundipharma, GSK, Serenity, Ferring and Romark, and has served on an advisory board for GSK. Joel Lexchin has received consultant fees from the US Agency for Healthcare Research and Quality for a project researching indication-based prescribing; and from the Government of Canada, the Ontario Supporting Patient-Oriented Research Support Unit and St. Michael’s Hospital Foundation for a project determining which drugs should be distributed free of charge by family physicians. He also received renumeration from The Canadian Institute for being on a panel that discussed a pharmacare plan for Canada. He is a member of the Foundation Board of Health Action International. No other competing interests were declared.
Similar articles
-
Measuring EHR pain points: high cost, poor functionality outweigh benefits, ease of access.Med Econ. 2014 Feb 10;91(3):28, 30. Med Econ. 2014. PMID: 25211941 No abstract available.
-
Exploring the remote release of information.J AHIMA. 2012 Oct;83(10):56-8. J AHIMA. 2012. PMID: 23061353 No abstract available.
-
Costs, control, data access remain top EHR concerns. Interview by Lois A Bowers.Med Econ. 2013 Jan 25;90(2):56, 59. Med Econ. 2013. PMID: 24066481 No abstract available.
-
Assessing the cost of electronic health records: a review of cost indicators.Telemed J E Health. 2010 Nov;16(9):963-72. doi: 10.1089/tmj.2010.0014. Epub 2010 Oct 19. Telemed J E Health. 2010. PMID: 20958197 Review.
-
A role for data: an observation on empowering stakeholders.Am J Prev Med. 2013 Jan;44(1 Suppl 1):S5-11. doi: 10.1016/j.amepre.2012.09.018. Am J Prev Med. 2013. PMID: 23195168 Review.
Cited by
-
The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.CMAJ Open. 2018 Feb 5;6(1):E63-E70. doi: 10.9778/cmajo.20180008. CMAJ Open. 2018. PMID: 29440236 Free PMC article.
-
Inciter les médecins à prescrire en se souciant davantage des coûts: Stratégie de changement.Can Fam Physician. 2020 Oct;66(10):e251-e254. Can Fam Physician. 2020. PMID: 33077464 Free PMC article. French. No abstract available.
-
Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study.CMAJ Open. 2019 Mar 29;7(1):E182-E189. doi: 10.9778/cmajo.20180108. Print 2019 Jan-Mar. CMAJ Open. 2019. PMID: 30926602 Free PMC article.
-
Where Do Real-Time Prescription Benefit Tools Fit in the Landscape of High US Prescription Medication Costs? A Narrative Review.J Gen Intern Med. 2023 Mar;38(4):1038-1045. doi: 10.1007/s11606-022-07945-z. Epub 2022 Nov 28. J Gen Intern Med. 2023. PMID: 36441366 Free PMC article. Review.
-
Effectiveness of provider price display in computerized physician order entry (CPOE) on healthcare quality: a systematic review.J Am Med Inform Assoc. 2018 Sep 1;25(9):1228-1239. doi: 10.1093/jamia/ocy076. J Am Med Inform Assoc. 2018. PMID: 29982523 Free PMC article.
References
-
- Prescription medication use by Canadians aged 6 to 79. Ottawa: Statistics Canada; 2015. Available: www.statcan.gc.ca/pub/82-003-x/2014006/article/14032-eng.htm (accessed 2017 Nov. 1).
-
- Reichert S, Simon T, Ham EA. Physicians’ attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000;160:2799–803. - PubMed
-
- Cassels A, Lexchin J. Potential savings from therapeutic substitution of 10 of Canada’s most dispensed prescription drugs. In: Temple N, Thompson A, editors. Excessive medical spending: facing the challange. Oxford (UK): Radcliffe Publishing; 2007:80–92.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources